Health Innovation
5 University Spinouts Turning Grants Into Product Progress
DealBio tracks early-stage health and longevity startups across Europe and North America. These 5 university spinouts are using non-dilutive funding to move academic technologies toward products, pilots and clinical translation.
- University Spinout
- Non-Dilutive Funding
- Academic Founder
University spinouts often begin with years of research but still face a difficult commercial gap: turning a laboratory result into something that can be tested, manufactured and used outside the university.
These five spinouts show grants being used on that transition, from assay and prototype development to patient testing and preparation for a first clinical study.
At a Glance
- NanoZymeXSwitzerland2026University of Basel enzyme-delivery platform
- BlueRay PrecisionGermany2025Heidelberg CAR-T detection reagents
- UNOMRSwitzerland2025ETH Zurich single-molecule protein sensing
- MoleSenseSwitzerland2025EPFL sweat sensing for pregnancy monitoring
- LumoxNetherlands2025Utrecht light-activated cancer therapy
Developing lipid nanoparticle enzyme therapies for Pompe and other rare diseases.
- Country
Switzerland- Founded
- 2026
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why NanoZymeX stands out
NanoZymeX emerged from University of Basel research and reports CHF 1.4 million in grants and institutional support, including Venture Kick funding. That non-dilutive backing is supporting translation of its enzyme-delivery platform, while a 2026 peer-reviewed study found more than fivefold lower anti-drug antibody formation in mice.
What NanoZymeX is building
The startup encapsulates replacement enzymes in lipid nanoparticles designed to improve cellular uptake and reduce immune recognition. Its lead program targets Pompe disease, while the platform is designed to support other enzyme-deficiency disorders.
Developing research reagents to detect and measure CAR-T cells.
- Country
Germany- Founded
- 2025
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why BlueRay Precision stands out
BlueRay Precision was built from Heidelberg University Hospital research and received more than €1 million through EXIST Forschungstransfer. The funding helped move the university technology into usable CAR-T research reagents, which are already used at DKFZ, Heidelberg University Hospital and University Hospital Erlangen.
What BlueRay Precision is building
BlueRay Precision develops engineered protein reagents for detecting CD19 and BCMA CAR-T cells by flow cytometry. The products are designed to improve consistency across research workflows while using standard laboratory instruments.
03
UNOMR
Building nanopore sensors that analyze protein modifications one molecule at a time.
- Country
- Switzerland
- Founded
- 2025
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why UNOMR stands out
UNOMR grew from ETH Zurich nanopore research and has received CHF 150,000 from Venture Kick plus CHF 150,000 from Gebert Rüf Stiftung. The non-dilutive support is helping move the sensing platform beyond the lab, alongside a Nestlé project testing single-protein glycosylation measurement.
What UNOMR is building
The platform uses a tunable nanopore sensing gap to analyse proteins and their modifications one molecule at a time. Its first application focuses on glycosylation, with target-specific binders and repeated reads designed to reveal molecular variation that bulk measurements can average away.
Developing a sweat-sensing patch to monitor hormones and inflammation in pregnancy.
- Country
- Switzerland
- Founded
- 2025
- Sector
- Medtech
- Funding stage
- Seed or earlier
- Founders
Why MoleSense stands out
MoleSense builds on EPFL research in wearable sensing and was selected for SPRIND's Continuous Hormone Monitoring Challenge, providing access to up to €1.5 million in non-dilutive funding. Its Innosuisse-backed work with EPFL, CSEM and CHUV has helped move the patch into patient testing with obstetrics specialists in Lausanne.
What MoleSense is building
The patch stimulates and collects small sweat samples, routes them through microfluidic channels and uses DNA-based sensing elements to detect hormones and inflammatory proteins. Software tracks changes against each wearer's baseline to support repeated monitoring during pregnancy.
05
Lumox
Developing a light-activated cancer therapy designed to spare healthy tissue.
- Country
Netherlands- Founded
- 2025
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why Lumox stands out
Lumox licenses two core Utrecht University patents and has secured more than €4.5 million from KWF for a planned first patient study in head and neck cancer. Here, non-dilutive funding is tied directly to the next translational step, while veterinary use provides an additional bridge from university research toward human clinical development.
What Lumox is building
Lumox links a tumour-targeting nanobody to a light-activated payload. The drug is intended to accumulate in tumour cells and become active only where red light is applied, combining molecular targeting with spatial control.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
Investment perspective
For a university spinout, the useful part of a grant is the step it makes possible outside the lab. Here, the funding is tied to productization: usable reagents, patient testing, an industry project and preparation for a first clinical study.
That gives investors something more concrete to assess than academic pedigree alone. A grant becomes more informative when it moves the technology into a customer, patient or development setting and starts to test whether the science can survive the transition into a startup product.
Methodology
DealBio selected these startups from its database of early-stage health and longevity startups, focusing on university spinouts with academic founders and meaningful non-dilutive or institutional funding. The selection spans therapeutics, research tools and monitoring technologies, with each startup showing a clear use of funding toward translation or product development.
DealBio builds its Startup Briefs using publicly available company materials, ecosystem sources, market references and professional profiles.